The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | The CAR FACTORY network: developing genetically optimized CAR-T and CAR-NK cellular therapies
In this video, Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, introduces the CAR FACTORY consortium. This Germany-wide research network, funded by the German Cancer Aid, aims to strengthen preclinical drug development at several universities and develop genetically optimized CAR-T and CAR-NK cellular therapies against malignancies such as multiple myeloma (MM) and acute myeloid leukemia (AML). This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
At this year’s EBMT meeting, it’s indeed a great pleasure for us that we received the Best Abstract Award in Basic Science for one of our projects in the frame of the newly founded CAR Factory Consortium. What’s the CAR Factory Consortium? Together with my co-speaker Michael Hudecek, we recently established the so-called CAR Factory with the aim to support acceleration of all translational steps required for bringing CAR-immune cell therapy to the clinic...
At this year’s EBMT meeting, it’s indeed a great pleasure for us that we received the Best Abstract Award in Basic Science for one of our projects in the frame of the newly founded CAR Factory Consortium. What’s the CAR Factory Consortium? Together with my co-speaker Michael Hudecek, we recently established the so-called CAR Factory with the aim to support acceleration of all translational steps required for bringing CAR-immune cell therapy to the clinic. The idea came with an initiative of the German Cancer Aid setting up this priority program to strengthen preclinical drug development at German universities.
It is our common goal to create a German-wide network that brings together expertise from not only medicine, but also biology, pharmaceutical chemistry, pharmacology, and immunotherapy. And what we could reach so far is that we build strong synergies to optimize CAR design along with advanced immune cell editing. Beyond lentiviral and retroviral transduction methods, we apply innovative CRISPR nuclease and base editing approaches allowing precise genetic disruption of genes responsible for immunosuppressive pathways. And our common main interest is the translation of cell and gene therapy for hematological diseases such as leukemia and multiple myeloma as we have reported at the EBMT meeting, but we are also successful in treatment concepts against solid cancer.
We truly believe that the CAR Factory will accelerate clinical translation of the newly advanced immunotherapeutics using CAR-engineered and CRISPR-edited immune cells such as CAR-T and NK cells. I am very thankful for the great spirit amongst all participating colleagues of this consortium from Freiburg, Würzburg, and Leipzig and for the important support we receive from the German Cancer Aid.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
CRIION, BMS.
